- Post-Effective Amendment to an S-8 filing (S-8 POS)
31 December 2010 - 4:59AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on December 30, 2010.
Registration No. 333-20239
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
VIA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(
State or other jurisdiction of
incorporation or organization
)
|
|
33-0687976
(
I.R.S. Employer
Identification No.
)
|
750 Battery Street, Suite 330
San Francisco, CA 94111
(Address of principal executive offices)
1995 STOCK PLAN
1995 DIRECTOR OPTION PLAN
(full title of the plans)
|
|
|
|
|
Copy to
:
|
Lawrence K. Cohen
|
|
Richard S. Meller, Esq.
|
President and Chief Executive
Officer
|
|
Latham & Watkins LLP
|
VIA Pharmaceuticals, Inc.
|
|
Sears Tower, Suite 5800
|
750 Battery Street, Suite 330
|
|
233 South Wacker Drive
|
San Francisco, CA 94111
|
|
Chicago, Illinois 60606
|
(415) 283-2200
|
|
(312) 876-7700
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated
filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
o
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
þ
|
|
|
|
|
(do not check if a smaller reporting company)
|
|
|
DEREGISTRATION OF SECURITIES
VIA Pharmaceuticals, Inc. (the Company) is filing this Post-Effective Amendment No. 1 to
Form S-8 Registration Statement to deregister all shares of the Companys common stock, $0.001 par
value per share (Common Stock), that remain unsold as of the date hereof under the Registration
Statement on Form S-8 (File No. 333-20239) originally filed by Urogen Corp. with the Securities and
Exchange Commission on January 23, 1997 (the Registration Statement). The Registration Statement
registered 1,850,000 shares of Common Stock for sale pursuant to the 1995 Stock Plan and 100,000
shares pursuant to the 1995 Director Option Plan.
This offering has been terminated because the Company intends to deregister its Common Stock
under the Securities Exchange Act of 1934, as amended. Consequently, the Company hereby terminates
the effectiveness of the Registration Statement and removes from registration any and all
securities of the Company that are registered but unsold under the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant certifies that it has
reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has
duly caused this Post-Effective Amendment No. 1 to Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the city of San Francisco, California, on
December 30, 2010.
|
|
|
|
|
|
VIA PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Lawrence K. Cohen
|
|
|
|
Lawrence K. Cohen
|
|
|
|
President and Chief Executive Officer
|
|
Pursuant to the requirements of the Securities Act, this Post-Effective Amendment No. 1 to
Registration Statement has been signed by the following persons in their respective capacities with
VIA Pharmaceuticals, Inc. and on the dates indicated.
|
|
|
|
|
Signatures
|
|
Titles
|
|
Date
|
|
|
|
|
|
/s/ Lawrence K. Cohen
Lawrence K. Cohen
|
|
Director, President and Chief Executive Officer
|
|
December 30, 2010
|
|
|
|
|
|
/s/ Douglass
B. Given
Douglass
B. Given
|
|
Chairman of the Board of Directors
|
|
December 30, 2010
|
|
|
|
|
|
/s/ Mark
N.K. Bagnall
Mark
N.K. Bagnall
|
|
Director
|
|
December 30, 2010
|
|
|
|
|
|
/s/ Fred B. Craves
Fred B. Craves
|
|
Director
|
|
December 30, 2010
|
|
|
|
|
|
/s/ David T. Howard
David T. Howard
|
|
Director
|
|
December 30, 2010
|
|
|
|
|
|
/s/ John R. Larson
John R. Larson
|
|
Director
|
|
December 30, 2010
|
VIA Pharmaceuticals (CE) (USOTC:VIAP)
Historical Stock Chart
From May 2024 to Jun 2024
VIA Pharmaceuticals (CE) (USOTC:VIAP)
Historical Stock Chart
From Jun 2023 to Jun 2024